The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Morbelli S.
Last
2022-01-01

Abstract

The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.
2022
49
2
632
651
Dementia; Encephalitis; Epilepsy; Glioma; Glucose; Lymphoma; Metabolism; Movement disorders; Oncology; PET; Psychiatry; Brain; Humans; Positron-Emission Tomography; Tomography; X-Ray Computed; Fluorodeoxyglucose F18; Nuclear Medicine
Guedj E.; Varrone A.; Boellaard R.; Albert N. L.; Barthel H.; van Berckel B.; Brendel M.; Cecchin D.; Ekmekcioglu O.; Garibotto V.; Lammertsma A. A.; Law I.; Penuelas I.; Semah F.; Traub-Weidinger T.; van de Giessen E.; Van Weehaeghe D.; Morbelli S.
File in questo prodotto:
File Dimensione Formato  
259_2021_Article_5603.pdf

Accesso aperto

Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1956353
Citazioni
  • ???jsp.display-item.citation.pmc??? 44
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 66
social impact